Effect of Rifampicin on the Pharmacokinetics of Lenvatinib in Healthy Adults

BACKGROUND AND OBJECTIVES: Lenvatinib is an oral, multitargeted tyrosine kinase inhibitor under clinical investigation in solid tumours. This study evaluated the influence of P-glycoprotein (P-gp) inhibition (single-dose rifampicin) and simultaneous cytochrome P450 3A4 (CYP3A4)/P-gp induction (multi...

Descripción completa

Detalles Bibliográficos
Autores principales: Shumaker, Robert C., Aluri, Jagadeesh, Fan, Jean, Martinez, Gresel, Thompson, Gary A., Ren, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4143598/
https://www.ncbi.nlm.nih.gov/pubmed/25022720
http://dx.doi.org/10.1007/s40261-014-0217-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4143598/
https://www.ncbi.nlm.nih.gov/pubmed/25022720
http://dx.doi.org/10.1007/s40261-014-0217-y

Ejemplares similares